Infectious adverse events in patients with atopic dermatitis treated with baricitinib.

Abstract

Baricitinib is a JAK1-2 inhibitorrecently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2and 4mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eightclinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.